Diabete Claudio Maffeis

Presentazione sul tema: "Diabete Claudio Maffeis"— Transcript della presentazione:

1 Diabete Claudio Maffeis
UOC Pediatria Indirizzo Diabetologico e Malattie del Metabolismo Centro Regionale Diabetologia Pediatrica Centro di Riferimento Europeo per la Diabetologia Pediatrica Università e Azienda Ospedaliera Universitaria Integrata - Verona 1

2

3 IPERTENSIONE DISLIPIDEMIA DIABETE OBESITA’ ICTUS INFARTO MIOCARDIO TUMORI

4 Impact of access to genetic testing
Survey on etiological diagnosis of diabetes in 1244 Italian diabetic children and adolescents: Impact of access to genetic testing 0,2 4,9 91,8 Mozzillo E, Maffeis C, et al. Diabetes Res Clin Pract. 2015;107(3):e15-8

5 Incidenza di DMT1 Regione Veneto (2008-2012)
Incidenza media di DMT1 in Veneto : 16,5 nuovi casi per soggetti per anno Marigliano M, Maffeis C, et al. Diabetes Res Clin Pract. 2015

6 Prevalenza di DMT1 Regione Veneto
Prevalenza media di DMT1 in Veneto : 1,26 casi per soggetti di età 0-18 anni Marigliano M, Maffeis C, et al. Diabetes Res Clin Pract. 2015

7 Estimated 2002 incidence of T1DM (A) and T2DM (B) among
U.S. individuals aged <20 years by age and race/ethnicity. Imperatore G et al. Diab Care 2012

8 The Time Is Right for a New Classification System for Diabetes:
Rationale and Implications of the β-Cell–Centric Classification Schema Schwartz SS, et al. Diabetes 2016

9 Schwartz SS, et al. Diabetes 2016

10 A unified model of the relationship between environmental factors,
beta-cell endoplasmic reticulum stress, generation of neoautoantigesns (HIPs), and loss of immune tolerance that triggers islet autoimmunity Rewers & Ludvigsson Lancet 2016

11 Environmental triggers and protective factors for islet autoimmunity and promoters
of progression to type 1 diabetes for which an association has been suggested Rewers & Ludvigsson Lancet 2016

12 What are the fundamental determinants of metabolic control?
Insulin regimen Diet Exercise Structure of clinical care teams Motivation Family support Mental health Access to care Goal setting Family function Cameron & Wherrett. Lancet 2015;385:

13 obiettivi di trattamento
Variabilità glicemica Ipoglicemia Iperglicemia Malik FS & Taplin CE Pediatr Drugs 2014;16:141-50

14 Automonitoraggio CGM CSII Pancreas artificiale (CHC) insulina

15 Evidence of a Strong Association Between Frequency of Self-Monitoring of Blood Glucose and Hemoglobin A1c Levels in T1D Exchange Clinic Registry Participants 13 – 26 years 1 – 13 years Pumps 13 – 26 years 1 – 13 years Conclusions There is a strong association between higher SMBG frequency and lower HbA1c levels. It is important for insurers to consider that reducing restrictions on the number of test strips provided per month may lead to improved glycemic control for some patients with type 1 diabetes. 13 – 26 years Injections 1 – 13 years Means are adjusted for potential confounders Miller KM, et al. Diabetes Care 2013;36:

16

17 CGM

18 HbA1c according to insulin modality/CGM use status.
No CGM CGM No CGM CGM No CGM Injection Pump Foster NC, et al. Diabetes Care 2016;39:e81

19 Microinfusore di insulina

20 Long-term outcome of insulin pump therapy in children with T1D
assessed in a large population-based case–control study Non pump therapy Pump therapy Johnson SR, et al. Diabetologia 2013;56:2392–2400

21

22 Closed-loop system for type 1 diabetes therapy (artificial pancreas)
Atkinson MA et al. Lancet 2014

23 Algoritmo di controllo: prime applicazioni in uso oggi.

24 Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia
Bergenstal RM, et al. NEJM 2013;369:224-32

25 Efficacia del Pancreas Artificiale durante la notte

26 Effect of Sensor-Augmented Insulin Pump Therapy and Automated
Insulin Suspension vs Standard Insulin Pump Therapy on Hypoglycemia in Patients With T1D: a Randomized Clinical Trial. Ly TT, et al. JAMA. 2013;310:

27 Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp
Phillip M, et al NEJM 2013;368:824-33

28 Systematically In Silico Comparison of Unihormonal
and Bihormonal Artificial Pancreas Systems Glucose management results of the standard subject under 4 algorithms, where the whole testing duration is 24 h Gao X, et al. Computat Math Met Med, 2013

29 Systematically In Silico Comparison of Unihormonal
and Bihormonal Artificial Pancreas Systems The blood glucose curves of ten virtual subjects under two proposed therapies P-type therapy PD-type therapy Gao X, et al. Computat Math Met Med, 2013

30 Pancreas Artificiale: il progetto italiano in età pediatrica (Bardonecchia 2015).
Gruppo di Ricerca: Diabetologia Pediatrica di: Verona; Milano; Torino; Roma; Napoli. Università di Padova: Diabetologia dell’adulto e Ingegneria Medica Università di Pavia: Ingegneria Medica. Del Favero S et al. Diab Care 2016

31 DiAS (pancreas artificiale)
Sensore per la glicemia Microinfusore DiAS (pancreas artificiale)

32 32 bambini (età 5-9 anni)  randomizzati in due gruppi
3 giorni 3 giorni SAP (microinfusore + sensore) SAP (microinfusore + sensore A DiAS (pancreas artificiale) DiAS (pancreas artificiale) B

33

34

35

36 TeleMonitoraggio

37

38 Take home message La tecnologia consentirà a breve di disporre di strumenti dotati di intelligenza artificiale che potranno migliorare ulteriormente il controllo metabolico del diabete del bambino e dell’adolescente. Il pediatra insieme al paziente e alla sua famiglia dovrà quindi acquisire nuove competenze per assicurare un livello di cura ottimale del diabete.

39 The use and efficacy of continuous glucose monitoring in T1D
treated with insulin pump therapy: a randomised controlled trial Battelino T, et al. Diabetologia 2012;55: